Lung cancer patients may live longer with Alimta

	Tweet

Adding a little extra chemotherapy after finishing the initial course helped advanced lung cancer patients live longer without having their tumors grow or come back, researchers reported on Thursday.

Patients with advanced lung cancer who took Eli Lilly and Co’s Alimta after finishing their normal course of chemotherapy lived cancer-free for two months, or 40 percent, longer than patients who took a placebo.

The preliminary results released ahead of the annual meeting of the American Society of Clinical Oncology (ASCO) suggest that adding extra months of chemotherapy after a patient has finished the initial course, and before any tumors begin to come back, may help many live longer, doctors said.

As so-called progression-free survival translates into fewer symptoms, this could mean a significant benefit to the quality of life for lung cancer patients, experts said.

“This is the first study to show that lung cancer patients can benefit from maintenance therapy,” said Dr. Tudor Ciuleanu of the Iuliu Hatieganu University of Medicine and Pharmacy in Romania, who led the study.

Ciuleanu’s team is continuing the study to see whether adding Alimta, known generically as pemetrexed, helps overall survival as well.

Alimta is approved for a lung tumor called mesothelioma and also as a second-line treatment after progression for non-small-cell lung cancer.

As a result it is usually not prescribed for lung cancer until the tumors begin to come back. The study—released as ASCO published summaries of studies to be discussed in detail at its annual meeting later this month—suggests more patients might get Alimta even before their tumors start to come back.

BIG MARKET

That could mean many people. Lung cancer kills 1.3 million globally, and the American Cancer Society says lung cancer was diagnosed in 213,380 people in the United States in 2007, killing 160,390.

Only 15 percent of lung cancer patients are alive five years after their diagnosis because the cancer is usually advanced by the time it is detected.

Ciuleanu’s team studied 663 patients with stage 3 or 4 non-small-cell lung cancer who had already received a platinum-containing drug such as cisplatin or carboplatin. Of them, 441 were randomly assigned to receive Alimta infusions, and 222 patients got a placebo.

The Alimta patients enjoyed more than four months free of any tumor growth or return, compared to 2.6 months for those who got a placebo, Ciuleanu said. Full details will be released June 2 at the meeting in Chicago.

Overall, the patients given Alimta lived an average of 13 months compared to 10 months for the placebo group, but this data is not final, Ciuleanu said.

The people who got placebos did not get any more treatment, so it is unclear whether it was just getting any kind of chemo, or whether the Alimta had an effect that older chemotherapy drugs would not have had.

“Would one find similar results by giving another active anti-cancer drug after the initial period of chemotherapy, or would one find results by simply continuing chemo?” Dr. Richard Schilsky of the University of Chicago and president-elect of ASCO asked in a telephone briefing.

“I think these are questions that we can’t answer from the current data but would be interesting to think about.”

Analysts said the new indications could add $1 billion to Alimta’s market.

“We believe the market opportunity for Alimta is substantial, offering potential upside versus our 2012 forecast of $1.7 billion,” said Leerink Swann analyst Seamus Fernandez.

By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters Life!)

RELATED STORIES:
Women Smokers, Higher Risk But Lower Death Rates from Lung Cancer   Proton Therapy Safe, Effective for Early-Stage Lung Cancer Patients   Lung Cancer Experts Address Smoking Dangers on Kick Butts Day   Lung Cancer: Who is a Candidate for Surgery?   Sniffer dogs can be used to detect lung cancer   Certain Vitamin Supplements May Increase Lung Cancer Risk, Especially in Smokers   Long-Term Use of Nutrient Supplements May Increase Cancer Risk   Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis   Burning incense increases risk of respiratory tract cancers   Blood Test for Lung Cancer May be Possible   New Approach Uses a Common Virus to Combat Deadly Lung Cancer   Lung cancer no more fatal to women non-smokers   Small Steps Toward Lung Cancer Relief   Lung Cancer Doesn’t Just Target Smokers   Wood smoke may raise lung cancer risk   Potential Early Warning System for Lung Cancer Identified   New research confirms need for lung cancer testing   Vitamins don’t reduce risk of lung cancer   Heavy marijuana use not linked to lung cancer   Cellular clues to vitamin A resistance in lung cancer   Lung cancer pill on NHS in 2007   Psychiatric symptoms can be first sign of cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]